Cryo-Cell International, Inc.CCELNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank72
5Y CAGR-39.6%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-39.6%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 37.58% |
| Q3 2025 | -53.21% |
| Q2 2025 | 34.20% |
| Q1 2025 | -67.78% |
| Q4 2024 | 57.08% |
| Q3 2024 | -19.56% |
| Q2 2024 | -52.06% |
| Q1 2024 | 13.31% |
| Q4 2023 | 28.96% |
| Q3 2023 | 12.95% |
| Q2 2023 | 286.49% |
| Q1 2023 | 3.18% |
| Q4 2022 | -4.82% |
| Q3 2022 | -0.77% |
| Q2 2022 | -45.05% |
| Q1 2022 | 657.66% |
| Q4 2021 | 94.23% |
| Q3 2021 | 209.05% |
| Q2 2021 | -47.71% |
| Q1 2021 | -12.32% |
| Q4 2020 | 465.71% |
| Q3 2020 | -87.29% |
| Q2 2020 | 71.64% |
| Q1 2020 | -66.07% |
| Q4 2019 | 591.15% |
| Q3 2019 | -50.78% |
| Q2 2019 | -15.75% |
| Q1 2019 | -78.14% |
| Q4 2018 | 21.07% |
| Q3 2018 | -24.07% |
| Q2 2018 | 118.39% |
| Q1 2018 | -23.30% |
| Q4 2017 | 7635.84% |
| Q3 2017 | -97.44% |
| Q2 2017 | -39.52% |
| Q1 2017 | -21.61% |
| Q4 2016 | 35.30% |
| Q3 2016 | 14.95% |
| Q2 2016 | 38.05% |
| Q1 2016 | -34.75% |